ClinicalTrials.gg
RecruitingNCT06010251Updated Oct 15, 2026

Utility of Multisensory Body-Representation in Spinal Cord Injury (SCI) With Pain

An interventional study of tDCS and bodily illusions in Spinal Cord Injuries and Neuropathic Pain, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Miami · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Spinal Cord Injuries by University of Miami — 12 open to participants now, 14 under way, 1 of them phase 3. Spinal Cord Injuries · University of Miami.

Planned enrollment
14th of 37
30 · median 26
Started
2023
with 4 others
No phase
33 of 45
10 open now
Primary completion
2027-10
later than 7 of 13 live
Registered
36th of 45
by date

Among the 45 studies in Spinal Cord Injuries by University of Miami, this one is the 14th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2023, is one of 33 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 36th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

12 of the 45 studies in Spinal Cord Injuries by University of Miami are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Spinal Cord Injuries by University of Miami, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effectiveness of bodily illusions combined with transcranial direct current stimulation (tDCS) on neuropathic pain symptoms and sensory functions in participants with spinal cord injury (SCI) and neuropathic pain.

03

Conditions studied

  • Spinal Cord Injuries
  • Neuropathic Pain
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The study will be open to people of any ethnicity, racial background, and gender.

Inclusion criteria

Inclusion criteria:

SCI with Pain:

  1. Men or women
  2. fluent in English
  3. 18-70 years of age who have: (3a) Complete and incomplete SCI, level of injury (above L1); (3b) Persistent neuropathic pain started after the injury for a minimum of three months prior to entering the study that is at least moderate in severity, defined as ≥ 4 on a Numeric Rating Scale (NRS) ranging 0 to 10.

Exclusion criteria

Exclusion criteria:

Participants will be excluded if they have:

  1. Major psychiatric disease/disorder (self-reported);
  2. a significant neurological trauma (self-reported) other than SCI;
  3. a recent (one-year) history of alcohol or drug abuse assessed by the Drug Abuse Screening Test (DAST-10)
  4. history of visual and hearing loss not corrected
  5. history of epilepsy or seizures
  6. any metal implants in the head, or implanted devices such as cochlea implants or cardiac pacemakers.

We will not include any special population like:

Adults unable to consent Individuals who are not yet adults (infants, children, teenagers) Pregnant women Prisoners

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    SCI with pain

    Participants will undergo 2-4 weeks of combined intervention including transcranial direct current stimulation (tDCS) and bodily illusions (10 sessions total).

    Other: tDCS and bodily illusions

Interventions

  • OthertDCS and bodily illusions

    Participants will be required to perform (in person) 10 interventions over a time frame of 2-4 weeks. They can perform this everyday or for a minimum of 2-3 times per week over 4 weeks. Two types of illusions will be used 15 min each, the rubber hand illusion and the walking illusion to target upper and lower limbs. These procedures will impact the body representation of the participants resulting in bodily illusions.

06

What researchers measure

Primary outcomes

  1. Change in neuropathic pain severity assessed by Neuropathic Pain Symptom Inventory (NPSI)

    The NPSI is a self-reported, validated questionnaire that includes 10 items (on different pain sensations, e.g., burning, squeezing, electric-shock, etc.) used to evaluate the properties of neuropathic pain. Each item is scored on an 11-point NRS (0 meaning no symptom and 10 meaning worst symptom), with higher scores indicating more severe neuropathic pain symptoms.

    Time frame: Baseline, up to 4 weeks

  2. Change in neuropathic pain interference assessed by pain interference questionnaire.

    The questionnaire consists in a numerical rating of pain interference ranging from 0= No Interference to 10=Extreme interference with activities, mood and sleep

    Time frame: Baseline, up to 4 weeks

  3. Changes associated with sensory function/dysfunction assessed by quantitative sensory testing

    The sensory test assesses thermal thresholds and includes: cool detection threshold (CDT), warm detection threshold (WDT), cold pain threshold (CPT), hot pain threshold (HPT), all performed using the method of limits: 0 to 50 Celsius (ºC) all values will be reported in Celsius.

    Time frame: Baseline, up to 4 weeks

Secondary outcomes

  1. Change in manageable pain assessed by days of manageable pain questionnaire.

    This item specifies the total number of days with pain during the last 7 days, including today, and the response categories ranges from 0=none to 7=seven days.

    Time frame: Baseline, up to 4 weeks

  2. Changes of psychosocial assessed by Multidimensional Pain Inventory (pain severity subscale)

    Multidimensional Pain Inventory assesses the psychosocial impact of pain. This scale consists of three questions: 1) pain at the present moment; 2) pain during the past week and 3) suffering because of pain. The range of the responses are from 0 (no pain or suffering) to 6 (extreme pain or suffering) and the scores of these three questions will be summed to obtain a composite pain severity score.

    Time frame: Baseline, up to 4 weeks

  3. Change in Global impression of changes by PGIC questionnaire

    Patients' Global Impression of Changes (PGIC) assesses patients' perceptions of changes following treatment. It is a 7-point verbal scale, with the options ranging from "very much improved" (3), "much improved" (2), "minimally improved" (1), "no change" (0), "minimally worsened" (-1) "much worsened" (-2), and "very much worsened" (-3).

    Time frame: Baseline, up to 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2027, 48 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 48 months is above that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2023
First posted
Aug 24, 2023
StartActual
Oct 17, 2023
Primary completionEst.
Oct 20, 2027was Oct 2026
CompletionEst.
Oct 20, 2027was Oct 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 20, 2026→Oct 20, 2027
Oct 15, 2026
Study completion
Oct 20, 2026→Oct 20, 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Oct 20, 2026→Oct 20, 2027
    Study completion Oct 20, 2026→Oct 20, 2027
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06010251
Responsible party
Eva Widerstrom-Noga (Professor, University of Miami) — Principal investigator
First posted
Aug 24, 2023
Start date
Oct 17, 2023
Primary completion
Oct 20, 2027 (estimated)
Completion
Oct 20, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Eva Widerstrom-Noga, PhD
Contact
ewiderstrom-noga@med.miami.edu
(305)243-7125
Roberta Vastano, PhD
Contact
rxv331@miami.edu
754 207 3627
Eva Widerstrom-Noga, PhD
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion